Intuniv (Guanfacine) for ADHD

1. What Intuniv is

Intuniv is the brand name for extended-release guanfacine — a non-stimulant medication approved for ADHD in children and adolescents in most jurisdictions, and increasingly used off-label or with formal approval for adults.

The compound itself (guanfacine) is an alpha-2A adrenergic agonist that was originally developed as an antihypertensive (blood pressure) medication in the 1980s. The discovery that it specifically improved prefrontal cortex function led to its repurposing for ADHD, and the extended-release formulation (Intuniv) was approved for paediatric ADHD in 2009.

Key features that distinguish it from other ADHD medications:

• Not a controlled substance (no schedule classification)
• No addiction potential
• Once-daily dosing
• Acts on different neurotransmitter system than stimulants
• Generally sedating rather than activating
• Particularly effective for emotional regulation and anxiety

2. How it works

Guanfacine selectively activates alpha-2A adrenergic receptors in the prefrontal cortex — the brain region responsible for:

• Sustained attention
• Working memory
• Executive function
• Impulse control
• Emotional regulation
• Top-down inhibition of inappropriate behavioural responses

By activating these specific receptors, guanfacine improves the signal-to-noise ratio of neural communication in the prefrontal cortex. The practical effect: easier to maintain attention on chosen targets, easier to regulate emotional responses, easier to inhibit impulsive reactions.

The mechanism is fundamentally different from stimulants (methylphenidate, amphetamines) which boost dopamine and norepinephrine availability throughout the brain. Stimulants work by “turning up the volume” on dopaminergic systems; Intuniv works by “turning up the volume on the prefrontal cortex specifically.” These are complementary approaches, which is why combination therapy is common.

3. The evidence base

Intuniv has a solid evidence base for ADHD efficacy:

• Multiple randomised controlled trials in children showed effect sizes around 0.5-0.7 for ADHD symptoms
• Adult studies have been smaller but support efficacy, typically effect sizes 0.4-0.5
• Combination studies (stimulant + Intuniv) show additive benefit
• Specific evidence for tic suppression (alongside or instead of stimulants)
• Evidence for ADHD with co-occurring oppositional symptoms
• Long-term safety data from years of paediatric use is reassuring

The evidence is strong enough that Intuniv is established as a legitimate ADHD treatment option, particularly in paediatric ADHD. Adult use is increasingly supported as adult evidence accumulates.

4. Who Intuniv suits best

Specific patient profiles where Intuniv is often the better first or second-line choice:

• Adults with prominent emotional dysregulation. Where ADHD’s impact is more about emotional intensity than attention.
• RSD-dominant ADHD. When rejection-sensitive dysphoria is the most-disabling feature.
• Co-occurring anxiety. Where stimulants might worsen the anxiety component.
• Sleep difficulties. Intuniv’s sedating profile often improves sleep onset.
• Tic disorders. Tourette’s or chronic tics where stimulants might exacerbate tics.
• Cardiovascular concerns. Some patients can’t use stimulants due to heart conditions.
• Substance-use history. Avoiding controlled substances.
• Stimulant non-responders. Adults who tried stimulants without adequate benefit.
• Stimulant intolerance. Adults who had unacceptable side effects on stimulants.
• Aggressive or oppositional behaviour. Particularly in children/adolescents with ADHD+ODD pattern.

The unifying theme: when emotional regulation, sleep, or anxiety dominate over pure attention difficulty, Intuniv is often the better first try.

5. Dosing and titration

Standard dosing approach:

• Adults: Start at 1mg/day, titrate up by 1mg per week to target 3-7mg/day. Doses above 7mg rarely used.
• Children/adolescents: Weight-based dosing, typically starting 1mg, titrating to 1-4mg or weight-adjusted range.
• Timing: Once daily, usually at bedtime because of sedating effects.
• With/without food: Avoid high-fat meals with dosing (alters absorption). Generally taken consistently with or without food.

Important notes on titration:

• Slower titration than stimulants (weeks vs days)
• Full therapeutic effect often takes 4-6 weeks at target dose
• Too-fast escalation produces sedation, dizziness, and cardiovascular side effects
• Patient compliance is highest when titration is gradual and side effects don’t overwhelm

6. Side-effect profile

Common side effects (typically dose-related and often improving over 2-4 weeks):

• Sedation / fatigue. The most-cited side effect. Often substantial in first weeks. Aligns with bedtime dosing for many.
• Dry mouth
• Constipation
• Decreased appetite (less than with stimulants)
• Headache
• Abdominal pain
• Dizziness on standing (orthostatic hypotension)
• Slowed heart rate

Less common but important:

• Significant blood pressure drops
• Bradycardia (slow heart rate)
• Fainting (especially with too-fast titration)
• Rebound hypertension if stopped abruptly
• Mood changes including depression in some adults

Monitoring: baseline and follow-up blood pressure + heart rate are typical. ECG sometimes recommended pre-treatment.

7. The sedation question

Sedation is the side effect that limits Intuniv use for many adults. Patterns:

• Sedation is usually strongest in first 2-4 weeks
• Many adults find it settles substantially after that period
• Some adults find persistent sedation throughout treatment
• Bedtime dosing aligns the sedation with sleep, making it often welcome rather than disabling
• Morning dosing often produces unworkable daytime sedation
• Combination with caffeine partially offsets daytime sedation for some

Strategies for managing sedation:

• Bedtime-only dosing (most common approach)
• Slower titration if sedation is severe
• Lowest effective dose to minimise sedation
• Combination with morning stimulant to balance arousal
• Accepting that 2-4 week settling period requires patience

8. Intuniv vs stimulants

The comparison:

• Efficacy on core ADHD symptoms. Stimulants larger effect (0.8-1.0) vs Intuniv (0.4-0.5).
• Efficacy on emotional regulation. Intuniv often outperforms stimulants for adults whose dominant problem is RSD or emotional intensity.
• Onset. Stimulants work within hours; Intuniv requires 2-4 weeks for substantial effect.
• Controlled-substance status. Stimulants Schedule II; Intuniv unscheduled.
• Addiction potential. Stimulants have it (low at therapeutic doses); Intuniv essentially none.
• Sleep effects. Stimulants often disrupt sleep; Intuniv often improves sleep.
• Anxiety effects. Stimulants can worsen anxiety; Intuniv often reduces it.
• Cardiovascular load. Stimulants raise BP and HR; Intuniv lowers them (potentially problematic if BP/HR already low).

For most ADHD adults without specific contraindications, stimulants remain first-line. Intuniv is the right choice when the specific profiles in section 4 apply.

9. Intuniv vs clonidine

Both are alpha-2 agonists used for ADHD. Differences:

• Receptor selectivity. Guanfacine more selective for alpha-2A (prefrontal cortex); clonidine acts on broader alpha-2 receptors throughout brain and body.
• Sedation. Clonidine more sedating overall; Intuniv produces less sedation at therapeutic doses.
• Half-life. Intuniv 16-18 hours, supporting once-daily; clonidine 12-16 hours, often requiring multiple doses or extended-release.
• ADHD efficacy. Intuniv generally edges out clonidine for ADHD symptoms specifically.
• Best use case for each. Intuniv: ADHD with RSD or emotional dysregulation. Clonidine: ADHD with severe insomnia or sensory regulation needs.

See our clonidine for ADHD guide for the comparison.

10. Intuniv vs atomoxetine

Both are non-stimulant ADHD options but work differently:

• Atomoxetine (Strattera). Selective norepinephrine reuptake inhibitor. Affects multiple brain regions. Different mechanism than alpha-2 agonists.
• Intuniv. Alpha-2A agonist. Specifically prefrontal cortex.
• Sedation. Intuniv much more sedating than atomoxetine.
• Onset. Both require weeks for full effect.
• Side-effect profile. Different patterns. Atomoxetine: GI effects, sexual side effects, sometimes liver issues. Intuniv: sedation, cardiovascular effects.
• Sleep. Intuniv often helps sleep; atomoxetine sometimes disrupts it.

For ADHD with prominent anxiety and sleep difficulty: Intuniv often preferred. For pure ADHD without those features: atomoxetine often preferred. Both can be combined with stimulants.

11. Combination therapy

Stimulant + Intuniv combination is common and well-supported:

• Addresses different ADHD dimensions: stimulant covers attention/hyperactivity; Intuniv addresses regulation, sleep, RSD
• Additive efficacy without significant pharmacological conflict
• Bedtime Intuniv + morning stimulant pattern is most common
• Allows lower dose of each medication for same effect
• Particularly useful for ADHD adults where neither medication alone fully addresses symptoms

Monitoring considerations when combining:

• Cardiovascular effects need careful watching (stimulants raise HR/BP, Intuniv lowers them — net effect varies by person)
• Total side-effect burden may compound
• Drug interactions with other medications more complex

This is firmly a prescriber decision.

12. Intuniv and RSD

One of Intuniv’s strongest use cases. Alpha-2 agonists have specific effects on the emotional regulation circuits that produce RSD episodes.

Reports from adults with prominent RSD on Intuniv:

• Substantial reduction in RSD episode frequency
• When episodes do occur, intensity is lower
• Recovery time after episodes often shorter
• Some find it the most-effective single intervention for RSD they’ve tried

The combination of stimulant + Intuniv is sometimes specifically chosen to address ADHD attention plus RSD emotional regulation together. For adults whose RSD is the most-disabling part of their ADHD, raising Intuniv with a prescriber is reasonable. See our RSD guide.

13. Intuniv and sleep

Many adults find Intuniv substantially improves their sleep as a side effect of its sedating profile.

Mechanisms:

• Direct sedation effect from alpha-2 agonism
• Reduces racing thoughts at bedtime (alpha-2 agonists generally calming)
• Lowers the arousal that ADHD adults often run with
• Doesn’t significantly affect sleep architecture in most adults (unlike some sedative medications)

Patterns:

• Bedtime dosing produces sleep onset within an hour for many
• Through-the-night sleep continuity often improves
• Morning grogginess can occur, particularly during titration
• For ADHD adults with delayed sleep phase, Intuniv can partially shift the sleep window earlier

Some prescribers use Intuniv specifically for the sleep benefit alongside ADHD treatment.

14. Stopping safely

Intuniv should never be stopped abruptly. Physical dependence develops at therapeutic doses, and sudden discontinuation can produce:

• Rebound hypertension. Blood pressure can rise to dangerously high levels.
• Rebound tachycardia. Heart rate elevation.
• Headache, anxiety, agitation.
• Symptoms similar to overdose of stimulants (the body’s alpha-2 system rebounds in the absence of the suppression).

Standard discontinuation: gradual taper over 1-2 weeks under medical supervision, typically reducing by 1mg per week. For higher doses, slower taper may be appropriate. Never stop abruptly without prescriber guidance.

15. FAQ